Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -314 | -2K | -3K |
| Operating Income | -4M | 141K | -248K | -5M | -915K |
| EBITDA | -380K | 255K | -247K | -555K | -913K |
| Net Income | -4M | -687K | -876K | -5M | -936K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0005
+0.00% today
1Y Change
-87.50%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Actavia Life Sciences, Inc. (RASP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 87.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +23.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +23.0%, free cash flow +97.3% with operating margin 0.0% and ROIC 242.9%. Stock Foundry combines RASP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RASP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RASP Max Drawdown
-87.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RASP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$936.4K
+82.5% YoY
Free Cash Flow
-$92.6K
+63.1% YoY
Revenue Growth
+0.0%
EPS Growth
+23.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -314 | -2K | -3K |
| Operating Income | -4M | 141K | -248K | -5M | -915K |
| EBITDA | -380K | 255K | -247K | -555K | -913K |
| Net Income | -4M | -687K | -876K | -5M | -936K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 75K | 39K | 11K | 14K | 50K |
| Total Assets | 96K | 85K | 45K | 33K | 5M |
| Total Liabilities | 2M | 2M | 3M | 3M | 2M |
| Shareholder Equity | -2M | -2M | -3M | -3M | 3M |
| Total Debt | 211K | 220K | 592K | 522K | 265K |
| Net Debt | 136K | 180K | 581K | 508K | 215K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
93K
+63.1% YoY
Capital Expenditures
0
Free Cash Flow
93K
+63.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
243.8%
Debt / Equity
-0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.